Clinical Interventions in Aging (Apr 2021)
Age-Related Clinical Outcomes of Patients with Non-Valvular Atrial Fibrillation: Insights from the COOL-AF Registry
Abstract
Rungroj Krittayaphong,1 Thanita Boonyapiphat,2 Chaiyasith Wongvipaporn,3 Poom Sairat1 On behalf of the COOL-AF Investigators1Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 2Division of Cardiology, Department of Medicine, Lampang Hospital, Lampang, Thailand; 3Division of Cardiology, Department of Medicine,Srinakarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, ThailandCorrespondence: Rungroj KrittayaphongDivision of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, ThailandTel +66 2-419-6104Fax +66 2-412-7412Email [email protected]: We aimed to compare the rate of clinical outcomes among three age groups (< 65, 65– 74, and ≥ 75 years) of adult patients with non-valvular atrial fibrillation (NVAF).Patients and Methods: We prospectively enrolled NVAF patients from 27 Thailand medical centers. The following were collected at baseline: demographic data, risk factors, comorbid conditions, laboratory data, and medications. The clinical outcomes were ischemic stroke (IS) or transient ischemic attack (TIA), major bleeding (MB), intracerebral hemorrhage (ICH), heart failure (HF), and death. All events were adjudicated. Patients were categorized according to age group into three groups; age < 65, 65– 74, and ≥ 75 years.Results: Among the 3402 patients that were enrolled during 2014– 2017, the mean age was 67.4± 11.3 years, and 2073 (60.9%) were older. The average follow-up was 25.7± 10.6 months. Oral anticoagulants were given in 75.4% of patients (91.1% of OAC was warfarin). The incidence rate of IS/TIA, MB, ICH, HF, and death was 1.43 (1.17– 1.74), 2.11 (1.79– 2.48), 0.70 (0.52– 0.92), 3.03 (2.64– 3.46), and 3.77 (3.33– 4.24) per 100 person-years, respectively. The risk of IS/TIA, MB, ICH, HF, and death increased with age both before and after adjustment for potential confounders. Even though OAC reduced the risk of IS/TIA, it increased the risk of MB. Net clinical benefit (NCB) analysis favored oral anticoagulant (OAC) in the high-risk subset of older adults.Conclusion: Older adult NVAF patients had a significantly increased risk of IS/TIA, MB, ICH, HF, and death compared to younger NVAF before and after adjustment for potential confounders. Strategies to reduce overall risk, including OAC use and choice and integrated care, should be implemented.Keywords: age-related clinical outcomes, patients, non-valvular atrial fibrillation, NVAF, COOL-AF registry, Thailand
